Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic ...

Discover the latest advancements in multiple sclerosis (MS) treatment, including innovative therapies and strategies for ...

The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, everyone. Welcome to BeOne Q2 2025 Earnings Call Webcast. [Operator Instructions] At this time, I would like to turn the call over ...

Key Points Non-GAAP earnings per share (EPS) of $2.25 in Q2 2025 far surpassed the analyst estimate of $0.32 and rose 923% year-over-year compared to Q2 2024 (non-GAAP adjusted diluted EPS per ADS).

Discover BeOne Medicines' robust Q2 2025 performance, with 42% revenue growth, market leadership in oncology, and raised 2025 guidance.

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

Q2 2025 Earnings Call Transcript August 5, 2025 Curis, Inc. beats earnings expectations. Reported EPS is $-0.68049, ...

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...

Discover Curis, Inc.'s Q2 2025 earnings insights! Learn about emavusertib's progress, upcoming studies, milestones, and financial outlook.

An 89-year-old White male underwent routine cataract surgery and insertion of two iStent Inject microstents (Glaukos ...